5-YEAR OUTCOMES FROM KEYNOTE-189 STUDY: PEMBROLIZUMAB PLUS PEMETREXED AND PLATINUM IN METASTATIC NONSQUAMOUS NON-SMALL-CELL LUNG CANCER

Abstract

Pembrolizumab is the PD-1 inhibitor approved for metastatic non-small cell lung cancer (NSCLC) monotherapy for patients with tumors that produce high PD-L1 level or combined with chemotherapy, regardless of tumor PD-L1 expression. In phase 3 KEYNOTE-189 study, 5-year data update, pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of PD-L1 expression. These data continue to support pembrolizumab in combination with pemetrexed-platinum as a standard of care in previously untreated metastatic non–small-cell lung cancer without EGFR mutations or ALK translocations.